Effect of hyperglycemia and empagliflozin on markers of cardiorenal injury and inflammation in patients with type 1 diabetes
Luxcia Kugathasan(University of Toronto), David Z.I. Cherney(University Health Network), Bruce A. Perkins(Sinai Health System), Andrew Advani(St. Michael's Hospital), Yuliya Lytvyn(University Health Network), Vikas S. Sridhar(University Health Network), Leif Erik Lovblom(Mount Sinai Hospital)
Cited by 6
Related Papers
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|1k
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
|Circulation|2017|470
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
|Nephrology Dialysis Transplantation|2019|216
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
|Nephrology Dialysis Transplantation|2020|189
Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus
|American Journal of Physiology-Renal Physiology|2014|173